Lirafugratinib (hydrochloride)
Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib hydrochloride covalently binds to Cys491. Lirafugratinib hydrochloride targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs[1].
Product Specifications
CAS Number
[2688040-45-9]
Product Name Alternative
RLY-4008 (hydrochloride)
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
FGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lirafugratinib-hydrochloride.html
Purity
98.96
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C(C)=C)NC1=CC=C(C2=C(C3=C(N)N=CN=C3N2C)C4=CC(F)=C(OC5=NC=CC(C)=N5)C=C4)C=C1.Cl
Molecular Formula
C28H25ClFN7O2
Molecular Weight
546.00
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Browse additional items from our catalog
ATP4B (Potassium-transporting ATPase Subunit beta, Gastric H (+) /K (+) ATPase Subunit beta, Proton Pump beta Chain) (PE)